SEC Form 4 · accession 0001209191-17-044648
Adamas Pharmaceuticals Inc · ADMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alfred G Merriweather
Officer — Chief Financial Officer
Period of report
Jul 10, 2017
Accepted (ET)
Jul 10, 2017 · 5:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 10, 2017 | A | 18,750 | $0.00 | A | 18,750 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $16.98 | Jul 10, 2017 | A | 112,500 | A | — | Jul 9, 2027 | Common Stock | 112,500 | 112,500 | D |
Explanation of responses
- F1Represents the grant of restricted stock units that vest 1/4th on each of September 20, 2018, September 20, 2019, September 20, 2020 and September 20, 2021.
- F2The shares subject to the option shall become vested according to the following schedule: 25% of the shares subject to the option shall vest on June 29, 2018, and the remaining shares will vest in equal monthly installments over the next 36 months.